Juan José Lasarte Sagastibelza-rekin lankidetzan egindako argitalpenak (21)

2023

  1. Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer

    EMBO Reports, Vol. 24, Núm. 8

  2. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

2022

  1. Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy

    OncoImmunology, Vol. 11, Núm. 1

2021

  1. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

2020

  1. Id1 and pd-1 combined blockade impairs tumor growth and survival of KRAS-mutant lung cancer by stimulating PD-l1 expression and tumor infiltrating CD8+ T cells

    Cancers, Vol. 12, Núm. 11, pp. 1-22

  2. Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade

    Nature cancer, Vol. 1, Núm. 1, pp. 75-85

  3. The involvement of ADAM10 in acantholysis in mucocutaneous pemphigus vulgaris depends on the autoantibody profile of each patient

    British Journal of Dermatology, Vol. 182, Núm. 5, pp. 1194-1204

2019

  1. PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas

    Blood, Vol. 133, Núm. 22, pp. 2401-2412

2017

  1. A combined PD-1/C5a blockade synergistically protects against lung cancer growth and metastasis

    Cancer Discovery, Vol. 7, Núm. 7, pp. 694-703

  2. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies

    Nature Communications, Vol. 8

2012

  1. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression

    Journal of Immunology, Vol. 189, Núm. 9, pp. 4674-4683

  2. Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses

    Vaccine, Vol. 30, Núm. 18, pp. 2848-2858

2005

  1. Is plasma cardiotrophin-1 a marker of hypertensive heart disease?

    Journal of Hypertension, Vol. 23, Núm. 3, pp. 625-632

2003

  1. Peptide inhibitors of hepatitis C virus NS3 protease

    Antiviral Chemistry and Chemotherapy, Vol. 14, Núm. 5, pp. 225-233

2002

  1. Inhibitory Effect against Polymerase and Ribonuclease Activities of HIV-reverse Transcriptase of the Aqueous Leaf Extract of Terminalia triflora

    Phytotherapy Research, Vol. 16, Núm. 8, pp. 778-780

1999

  1. Argentine plant extracts active against polymerase and ribonuclease H activities of HIV-1 reverse transcriptase

    Phytotherapy Research, Vol. 13, Núm. 3, pp. 206-209

  2. Synthesis and anti-HIV-1 activities of new pyrimido[5,4-b]indoles

    Farmaco, Vol. 54, Núm. 4, pp. 255-264

  3. T(h)1 but not T(h)0 cell help is efficient to induce cytotoxic T lymphocytes by immunization with short synthetic peptides

    International Immunology, Vol. 11, Núm. 12, pp. 2025-2033

1997

  1. Synthesis and evaluation of new Reissert analogs as HIV-1 RT inhibitors. 2. Benzo[f]quinoline and pyridine derivatives

    Drug Design and Discovery, Vol. 14, Núm. 4, pp. 291-303

  2. Synthesis and evaluation of new Reissert analogs as HIV-1 reverse transcriptase inhibitors. 1. Quinoline and quinoxaline derivatives

    Drug Design and Discovery, Vol. 14, Núm. 4, pp. 305-332